Business Wire

LUNAPHORE

6.2.2020 11:32:13 CET | Business Wire | Press release

Share
Lunaphore Receives CHF 23M Series C Financing, Led by PHC Holdings Corporation

Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research and tissue diagnostics, announces the first closing of its Series C funding, amounting to CHF 23M. The round was led by the Japanese strategic investor PHC Holdings Corporation (hereafter, PHCHD), a global healthcare company that owns Epredia, a leading provider of comprehensive solutions for precision cancer diagnostics.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200206005367/en/

The closing of the oversubscribed round was finalized on January 15, 2020. Existing investors including Redalpine Venture Partners, OCCIDENT and Alpana Ventures have also participated in this financing round.

“We are thrilled by the confidence placed in Lunaphore by our existing investors as well as the new ones in this financing round. The interest of global players in healthcare, like PHCHD demonstrates the relevance and added value of Lunaphore’s technology and confirms its high potential to transform the field of tissue analytics” said Ata Tuna Ciftlik, Lunaphore’s CEO, and added “We’re one step closer to fulfilling our vision of enabling highly sophisticated new-generation tissue analytics tests with our unique automation capabilities. The expertise and rapidly expanding network of the PHC Group and the specialist knowledge of the anatomical pathology field at Epredia will both help us gain scale and speed in this process”.

Lunaphore will invest the proceeds of Series C funding in market and product expansion. This includes a US market entry, the ramp up of activities in Europe and the development of next generation of instruments.

“We are delighted that PHCHD has invested in one of the most exciting players in tissue staining” said James Post, President of Epredia, a PHC Group portfolio company. “We believe that their technology has the potential to help revolutionize tissue analytics and greatly improve the workflow for pathologists and immuno-oncology researchers. We look forward to working together with Lunaphore to further develop their highly innovative solutions and bring them to market to help further enhance cancer research and diagnostics.” Mr. Post has joined Lunaphore’s Board of Directors as part of the transaction.

“This investment is a strong strategic fit for PHCHD, as we look to invest further in our diagnostics business,” explained Michael Kloss, President and CEO of PHCHD. “Lunaphore’s tissue staining products complement the portfolio we currently have in Epredia and we believe there is a strong opportunity for growth in their business.”

Epredia was created in June 2019 following the acquisition of Thermo Fisher Scientific’s Anatomical Pathology business by PHC Holdings Corporation. Epredia’s portfolio includes microscope slides, instruments and consumables and they are committed to providing high quality products and services to enhance precision cancer diagnostics.

About Lunaphore
Lunaphore Technologies S.A. is a Swiss company developing next generation tissue autostainers. The award-winning technology based on microfluidics is called FFeX (Fast Fluidic Exchange). It aims to perform assays much faster than standard techniques and has demonstrated good results in tests with cancer patient samples. Lunaphore was founded in 2014 with the vision of bringing –omics like approaches to tissue analytics and has been recognized as one of the most innovative companies nationally and internationally. For further information on Lunaphore and its products, please visit www.lunaphore.com .

About PHC Holdings Corporation
Incorporated in 2014, PHC Holdings Corporation is a global healthcare company with its subsidiaries including PHC Corporation, Epredia, LSI Medience Corporation and Ascensia Diabetes Care Holdings AG. Committed to its corporate mission, “We contribute to the wellbeing of society through our diligent efforts by creating new value propositions for all the people who wish for better health,” the company develops, manufactures, sells and services medical equipment and solutions across diabetes care, diagnostics, life sciences and healthcare services. PHC Holdings Corporation group’s consolidated net sales in FY2018 was 186.8 billion yen with global distribution of products and services in more than 125 countries. For further information on PHC Holdings Corporation, please visit www.phchd.com/global .  

About Epredia
Epredia is a global leader in the anatomical pathology field, providing comprehensive solutions for precision cancer diagnostics. Powered by key brands, including Erie, Menzel, Microm, Shandon, and Richard Allan, Epredia’s portfolio includes microscope slides, instruments and consumables. Established following the acquisition by PHC Holdings Corporation in 2019, Epredia has major sites in the United States, the United Kingdom, Germany, Switzerland and China with a total of around 1,200 employees. Epredia is committed to achieving its mission to improve lives by enhancing cancer diagnostics for patients around the world. For further information on Epredia and its products, please visit www.epredia.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/lunaphore

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Nordic Firms Seek Green, Sovereign AI Infrastructure14.7.2026 11:00:00 CEST | Press release

Renewable power, heat reuse and local data requirements are reshaping private and hybrid cloud choices, ISG Provider Lens® report says Nordic enterprises are adopting private and hybrid cloud infrastructure that combines AI-ready capacity, local residency and low-carbon operations as high-performance workloads and geopolitical risk reshape IT strategies, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The 2026 ISG Provider Lens® Private/Hybrid Cloud — Data Center Services report for the Nordics finds that the region is evolving from a hosting destination into a backbone for European data processing. Enterprises are using the Nordics’ renewable energy and natural cooling to support cloud strategies that balance large scale with environmental consciousness and compliance with data sovereignty regulations. “Nordic enterprises are connecting infrastructure decisions to resilien

European Commission Approves Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX for First-Line Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation14.7.2026 11:00:00 CEST | Press release

ERBITUX in combination with encorafenib and FOLFOX is the first and only approved targeted regimen for the first-line treatment of adult patients with BRAF V600E-mutant mCRCThe approval is based on the pivotal Phase 3 BREAKWATER trial, which demonstrated statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS) compared to standard chemotherapy with or without bevacizumabERBITUX confirms its status as the pioneering anti-EGFR therapy in mCRC, now approved across different patient populations and multiple lines of therapyNot intended for Canada-, UK- or US-based media Merck, a leading global science and technology company, today announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026. Erbitux is now indicated in combination with encorafenib for patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) — both in first-line treatment in combination

Swiss Pension Funds Increase Commitments to Record Infrastructure Equity Fund to EUR 1.23 Billion14.7.2026 09:58:00 CEST | Press release

Record Asset Management GmbH (RAM), subsidiary of London-listed Record plc (Record Financial Group), today announced that its Infrastructure Equity fund has attracted EUR 160 million of additional capital from Swiss pension funds, increasing total commitments to approximately EUR 1.23 billion. Capital deployment continues to progress in line with expectations, with more than one-third of the fund’s initial capital now deployed or committed to investments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713541233/en/ RAM manages a dedicated infrastructure co-investment vehicle in partnership with APG, the pension asset manager of ABP, providing Swiss pension funds with access to large-scale infrastructure equity investments alongside APG’s pension fund partners. RAM is the European asset management arm of Record Financial Group, the London-listed specialist investment group managing USD 115 billion of assets on behalf of in

Samsung Becomes a Sisvel Wi-Fi Multimode Pool Licensee and Licensor14.7.2026 09:09:00 CEST | Press release

Samsung Electronics has signed up as a licensee of the Sisvel Wi-Fi Multimode pool and has also become a licensor under the programme. The decision by the South Korean company - a global R&D powerhouse and among the world’s top smartphone vendors, as well as a leader in many other electronic product categories - not only confirms the Sisvel Wi-Fi Multimode pool as a recognised solution provider for parties seeking to derisk Wi-Fi implementation but also considerably expands the scope of the programme’s patent offering. Since it was publicly launched in January 2026, ASUS, Hewlett Packard Enterprise, Microsoft and Sony Group Corporation have become licensees of the Sisvel Wi-Fi Multimode pool. There are also five licensor/licensee companies: Huawei, Panasonic, Philips, Samsung Electronics and ZTE. The other licensors are KPN, Mitsubishi Electric, Orange, Aegis 11 SA, SK Telecom and Wilus. The agreement announced today ends litigation in the Eastern District of Texas between Samsung Elec

Wolters Kluwer Integrates Legal Intelligence Platform With Libra Legal AI Workspace in the Netherlands14.7.2026 09:00:00 CEST | Press release

Dutch legal professionals gain access to additional content sources in the Libra by Wolters Kluwer AI workspace, powering a new generation of AI-driven legal work Wolters Kluwer Legal & Regulatory today announced the integration of its Legal Intelligence multi-content-provider platform with the Libra by Wolters Kluwer AI workspace in the Netherlands. Dutch legal professionals will now be able to access more than 5000 additional pieces of expert legal content from Wolters Kluwer and third-party content providers as well as public sources in addition to the existing content offerings in Libra. “By bringing Legal Intelligence into Libra, we move beyond traditional search to truly integrated, AI-driven workflows,” said Rimco Spanjer, Vice President & Managing Director, Wolters Kluwer Legal & Regulatory Benelux. “Combining our authoritative content with trusted third-party sources in one AI workspace enables legal professionals to work smarter every day.” The integration will include truste

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye